<p>新泽西州公共养老金基金 D 在最近向证券交易委员会提交的 13F 表格中披露，在第四季度购买了 Agios Pharmaceuticals, Inc.（NASDAQ:AGIO - 免费报告）的新头寸。该公司购买了 47,414 股生物制药公司的股票，价值约为 1,291,000 美元。新泽西州公共养老金基金 D 在最近的报告期末持有 Agios Pharmaceuticals 约 0.08% 的股份。</p>
<p>获取 <strong>Agios Pharmaceuticals</strong> 的提醒：</p>
<p>其他几家机构投资者也对该公司的持仓进行了调整。Creative Planning 在第三季度将其在 Agios Pharmaceuticals 的股份增加了 2.2%。Creative Planning 目前拥有 13,119 股生物制药公司的股票，价值为 527,000 美元，此前在上个季度又购买了 280 股。Assetmark Inc.在第四季度将其在 Agios Pharmaceuticals 的股份增加了 37.9%。Assetmark Inc.目前拥有 1,317 股生物制药公司的股票，价值为 36,000 美元，此前在上个季度又购买了 362 股。制造商人寿保险公司在第二季度将其在 Agios Pharmaceuticals 的持股增加了 0.4%。制造商人寿保险公司目前拥有 132,083 股生物制药公司的股票，价值为 4,393,000 美元，此前在上个季度又购买了 512 股。未来资产全球投资有限公司在第四季度将其在 Agios Pharmaceuticals 的持股增加了 26.2%。未来资产全球投资有限公司目前拥有 2,834 股生物制药公司的股票，价值为 77,000 美元，此前在上个季度又购买了 588 股。最后，加拿大人寿保险公司在第三季度将其在 Agios Pharmaceuticals 的持股增加了 3.4%。加拿大人寿保险公司目前拥有 20,325 股生物制药公司的股票，价值为 796,000 美元，此前在上个季度又购买了 662 股。</p>
<h2>Agios Pharmaceuticals 股票表现</h2>
<p>AGIO 股票周一开盘价为 27.79 美元。该公司的 50 日移动平均价格为 29.70 美元，200 日移动平均价格为 30.59 美元。该股票的市值为 16.5 亿美元，市盈率为-3.83，贝塔值为 0.58。Agios Pharmaceuticals, Inc.的 52 周低点为 22.24 美元，52 周高点为 46.00 美元。</p>
<p>Agios Pharmaceuticals（NASDAQ:AGIO - 获取免费报告）最近于 4 月 29 日（星期三）发布了季度财报。该生物制药公司报告本季度每股收益为（1.69 美元），超出分析师一致预期的（1.81 美元）0.12 美元。Agios Pharmaceuticals 的股本回报率为-34.11%，净利润率为-639.84%。该公司本季度的收入为 2075 万美元，而一致预期为 1330 万美元。与去年同期相比，该公司的季度收入增长了 137.7%。整体来看，卖方分析师预测 Agios Pharmaceuticals, Inc.在本财年将发布-6.19 的每股收益。</p>
<h2>华尔街分析师观点</h2>
<p>AGIO 已成为几份研究报告的主题。花旗集团在 3 月 5 日的研究报告中将 Agios Pharmaceuticals 的目标价从 38.00 美元上调至 46.00 美元，并给予该公司 “买入” 评级。高盛集团在 4 月 1 日的研究报告中将 Agios Pharmaceuticals 的目标价从 28.00 美元上调至 32.00 美元，并给予该公司 “中性” 评级。Wall Street Zen 在 3 月 22 日的研究报告中将 Agios Pharmaceuticals 的评级从 “卖出” 上调至 “持有”。HC Wainwright 在 4 月 20 日的研究报告中将 Agios Pharmaceuticals 的目标价从 65.00 美元下调至 50.00 美元，并对该股票给予 “买入” 评级。最后，Weiss Ratings 在 3 月 27 日的报告中重申了对 Agios Pharmaceuticals 股票的 “卖出（d）” 评级。六位股票研究分析师对该股票给予了买入评级，四位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “持有”，平均目标价为 41.56 美元。</p>
<p><strong>查看我们关于 Agios Pharmaceuticals 的最新研究报告</strong></p>
<h2>Agios Pharmaceuticals 的内部交易</h2>
<p>在其他新闻中，内部人士 Tsveta Milanova 于 4 月 2 日（星期四）出售了 3,262 股公司的股票。该股票以平均价格 34.71 美元出售，总价值为 113,224.02 美元。出售后，内部人士直接持有该公司 46,829 股股票，价值为 1,625,434.59 美元。此次交易使其持股减少了 6.51%。该出售在向 SEC 提交的文件中披露，文件可在 SEC 网站上获取。该交易是在预先安排的 10b5-1 交易计划下执行的。出售是为了覆盖与股权奖励归属相关的税款扣缴义务。此外，内部人士 James William Burns 于 4 月 2 日（星期四）出售了 3,280 股公司的股票。该股票以平均价格 34.71 美元出售，总价值为 113,848.80 美元。出售完成后，内部人士持有该公司 49,306 股股票，价值约为 1,711,411.26 美元。此次交易代表其持股减少了 6.24%。有关此次出售的更多细节可在官方 SEC 披露中找到。该交易是在预先安排的 10b5-1 交易计划下执行的。出售是为了覆盖与股权奖励归属相关的税款扣缴义务。在上个季度，内部人士出售了价值 520,405 美元的 15,582 股公司股票。内部人士持有公司股票的 5.40%。</p>
<h2>关于 Agios Pharmaceuticals</h2>
<p>（免费报告）</p>
<p>Agios Pharmaceuticals, Inc 是一家生物制药公司，成立于 2008 年，源于 Dana-Farber 癌症研究所和 Broad Institute 的研究。公司总部位于马萨诸塞州剑桥，Agios 专注于理解和靶向细胞代谢，以开发针对癌症和罕见遗传疾病的新疗法。公司的科学平台整合了基因组发现、代谢谱分析和精准医学的方法，以识别和推进能够纠正或利用代谢功能障碍的小分子候选药物。</p>
<p>Agios 的主要产品是针对特定癌症突变的 IDH（异柠檬酸脱氢酶）抑制剂。</p>
<h2>另见</h2>
<ul>
<li>五只我们认为比 Agios Pharmaceuticals 更好的股票</li>
<li>超越 NVIDIA：强劲势头的 AI 相关投资</li>
<li>量子财报季正在升温——关注两大主要参与者</li>
<li>Flutter 在财报后看到提振，FanDuel 显示复苏迹象</li>
<li>3 只医疗保健股票将从这项重大法案中受益</li>
</ul>
<p><strong>想看看其他对 AGIO 感兴趣的对冲基金持有什么吗？</strong> 请访问 HoldingsChannel.com，获取 Agios Pharmaceuticals, Inc.（NASDAQ:AGIO - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUdJTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUdJTw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Agios Pharmaceuticals 吗？</h2>
<p>在考虑 Agios Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Agios Pharmaceuticals 并不在名单上。</p>
<p>虽然 Agios Pharmaceuticals 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Agios制药

<p>新泽西州公共养老金基金 D 在第四季度收购了 47,414 股 Agios Pharmaceuticals, Inc.（纳斯达克代码：AGIO），价值约为 129 万美元。其他机构投资者也调整了在该公司的持仓。Agios Pharmaceuticals 报告的季度收入为 2075 万美元，超出预期，且每股收益为负值（$1.69）。分析师对该股票的评级不一，平均目标价为 41.56 美元。内部人士 Tsveta Milanova 最近出售了 3,262 股，减少了其持股比例 6.51%</p>

<p>State of New Jersey Common Pension Fund D bought a new position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities &amp; Exchange Commission. The firm bought 47,414 shares of the biopharmaceutical company's stock, valued at approximately $1,291,000. State of New Jersey Common Pension Fund D owned approximately 0.08% of Agios Pharmaceuticals at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>新泽西州公共养老金基金 D 在最近向证券交易委员会提交的 13F 表格中披露，在第四季度购买了 Agios Pharmaceuticals, Inc.（NASDAQ:AGIO - 免费报告）的新头寸。该公司购买了 47,414 股生物制药公司的股票，价值约为 1,291,000 美元。新泽西州公共养老金基金 D 在最近的报告期末持有 Agios Pharmaceuticals 约 0.08% 的股份。</p>
</div><p>Get <strong>Agios Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Agios Pharmaceuticals</strong> 的提醒：</p>
</div><p>Several other institutional investors have also made changes to their positions in the company. Creative Planning increased its position in shares of Agios Pharmaceuticals by 2.2% in the third quarter. Creative Planning now owns 13,119 shares of the biopharmaceutical company's stock worth $527,000 after acquiring an additional 280 shares in the last quarter. Assetmark Inc. raised its position in Agios Pharmaceuticals by 37.9% during the fourth quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company's stock valued at $36,000 after acquiring an additional 362 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in Agios Pharmaceuticals by 0.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 132,083 shares of the biopharmaceutical company's stock worth $4,393,000 after purchasing an additional 512 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in Agios Pharmaceuticals by 26.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,834 shares of the biopharmaceutical company's stock valued at $77,000 after purchasing an additional 588 shares during the last quarter. Finally, CANADA LIFE ASSURANCE Co grew its holdings in Agios Pharmaceuticals by 3.4% during the third quarter. CANADA LIFE ASSURANCE Co now owns 20,325 shares of the biopharmaceutical company's stock valued at $796,000 after purchasing an additional 662 shares during the last quarter.</p>
<div class="lb-trans"><p>其他几家机构投资者也对该公司的持仓进行了调整。Creative Planning 在第三季度将其在 Agios Pharmaceuticals 的股份增加了 2.2%。Creative Planning 目前拥有 13,119 股生物制药公司的股票，价值为 527,000 美元，此前在上个季度又购买了 280 股。Assetmark Inc.在第四季度将其在 Agios Pharmaceuticals 的股份增加了 37.9%。Assetmark Inc.目前拥有 1,317 股生物制药公司的股票，价值为 36,000 美元，此前在上个季度又购买了 362 股。制造商人寿保险公司在第二季度将其在 Agios Pharmaceuticals 的持股增加了 0.4%。制造商人寿保险公司目前拥有 132,083 股生物制药公司的股票，价值为 4,393,000 美元，此前在上个季度又购买了 512 股。未来资产全球投资有限公司在第四季度将其在 Agios Pharmaceuticals 的持股增加了 26.2%。未来资产全球投资有限公司目前拥有 2,834 股生物制药公司的股票，价值为 77,000 美元，此前在上个季度又购买了 588 股。最后，加拿大人寿保险公司在第三季度将其在 Agios Pharmaceuticals 的持股增加了 3.4%。加拿大人寿保险公司目前拥有 20,325 股生物制药公司的股票，价值为 796,000 美元，此前在上个季度又购买了 662 股。</p>
</div><h2>Agios Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Agios Pharmaceuticals 股票表现</h2>
</div><p>Shares of AGIO stock opened at $27.79 on Monday. The firm's 50 day moving average price is $29.70 and its two-hundred day moving average price is $30.59. The stock has a market cap of $1.65 billion, a PE ratio of -3.83 and a beta of 0.58. Agios Pharmaceuticals, Inc. has a 52-week low of $22.24 and a 52-week high of $46.00.</p>
<div class="lb-trans"><p>AGIO 股票周一开盘价为 27.79 美元。该公司的 50 日移动平均价格为 29.70 美元，200 日移动平均价格为 30.59 美元。该股票的市值为 16.5 亿美元，市盈率为-3.83，贝塔值为 0.58。Agios Pharmaceuticals, Inc.的 52 周低点为 22.24 美元，52 周高点为 46.00 美元。</p>
</div><p>Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) EPS for the quarter, beating analysts' consensus estimates of ($1.81) by $0.12. Agios Pharmaceuticals had a negative return on equity of 34.11% and a negative net margin of 639.84%.The business had revenue of $20.75 million during the quarter, compared to the consensus estimate of $13.30 million. The company's quarterly revenue was up 137.7% compared to the same quarter last year. As a group, sell-side analysts predict that Agios Pharmaceuticals, Inc. will post -6.19 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Agios Pharmaceuticals（NASDAQ:AGIO - 获取免费报告）最近于 4 月 29 日（星期三）发布了季度财报。该生物制药公司报告本季度每股收益为（1.69 美元），超出分析师一致预期的（1.81 美元）0.12 美元。Agios Pharmaceuticals 的股本回报率为-34.11%，净利润率为-639.84%。该公司本季度的收入为 2075 万美元，而一致预期为 1330 万美元。与去年同期相比，该公司的季度收入增长了 137.7%。整体来看，卖方分析师预测 Agios Pharmaceuticals, Inc.在本财年将发布-6.19 的每股收益。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>AGIO has been the subject of several research reports. Citigroup increased their price objective on Agios Pharmaceuticals from $38.00 to $46.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, March 5th. The Goldman Sachs Group upped their target price on Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a &#34;neutral&#34; rating in a research note on Wednesday, April 1st. Wall Street Zen upgraded Agios Pharmaceuticals from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Sunday, March 22nd. HC Wainwright lowered their price target on Agios Pharmaceuticals from $65.00 to $50.00 and set a &#34;buy&#34; rating on the stock in a research report on Monday, April 20th. Finally, Weiss Ratings restated a &#34;sell (d)&#34; rating on shares of Agios Pharmaceuticals in a report on Friday, March 27th. Six equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of &#34;Hold&#34; and an average target price of $41.56.</p>
<div class="lb-trans"><p>AGIO 已成为几份研究报告的主题。花旗集团在 3 月 5 日的研究报告中将 Agios Pharmaceuticals 的目标价从 38.00 美元上调至 46.00 美元，并给予该公司 “买入” 评级。高盛集团在 4 月 1 日的研究报告中将 Agios Pharmaceuticals 的目标价从 28.00 美元上调至 32.00 美元，并给予该公司 “中性” 评级。Wall Street Zen 在 3 月 22 日的研究报告中将 Agios Pharmaceuticals 的评级从 “卖出” 上调至 “持有”。HC Wainwright 在 4 月 20 日的研究报告中将 Agios Pharmaceuticals 的目标价从 65.00 美元下调至 50.00 美元，并对该股票给予 “买入” 评级。最后，Weiss Ratings 在 3 月 27 日的报告中重申了对 Agios Pharmaceuticals 股票的 “卖出（d）” 评级。六位股票研究分析师对该股票给予了买入评级，四位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “持有”，平均目标价为 41.56 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on Agios Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Agios Pharmaceuticals 的最新研究报告</strong></p>
</div><h2>Insider Transactions at Agios Pharmaceuticals</h2>
<div class="lb-trans"><h2>Agios Pharmaceuticals 的内部交易</h2>
</div><p>In other news, insider Tsveta Milanova sold 3,262 shares of the business's stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $34.71, for a total value of $113,224.02. Following the sale, the insider directly owned 46,829 shares in the company, valued at $1,625,434.59. The trade was a 6.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider James William Burns sold 3,280 shares of the business's stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $34.71, for a total value of $113,848.80. Following the completion of the sale, the insider owned 49,306 shares in the company, valued at approximately $1,711,411.26. This trade represents a 6.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 15,582 shares of company stock valued at $520,405. Insiders own 5.40% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，内部人士 Tsveta Milanova 于 4 月 2 日（星期四）出售了 3,262 股公司的股票。该股票以平均价格 34.71 美元出售，总价值为 113,224.02 美元。出售后，内部人士直接持有该公司 46,829 股股票，价值为 1,625,434.59 美元。此次交易使其持股减少了 6.51%。该出售在向 SEC 提交的文件中披露，文件可在 SEC 网站上获取。该交易是在预先安排的 10b5-1 交易计划下执行的。出售是为了覆盖与股权奖励归属相关的税款扣缴义务。此外，内部人士 James William Burns 于 4 月 2 日（星期四）出售了 3,280 股公司的股票。该股票以平均价格 34.71 美元出售，总价值为 113,848.80 美元。出售完成后，内部人士持有该公司 49,306 股股票，价值约为 1,711,411.26 美元。此次交易代表其持股减少了 6.24%。有关此次出售的更多细节可在官方 SEC 披露中找到。该交易是在预先安排的 10b5-1 交易计划下执行的。出售是为了覆盖与股权奖励归属相关的税款扣缴义务。在上个季度，内部人士出售了价值 520,405 美元的 15,582 股公司股票。内部人士持有公司股票的 5.40%。</p>
</div><h2>About Agios Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Agios Pharmaceuticals</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company's scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.</p>
<div class="lb-trans"><p>Agios Pharmaceuticals, Inc 是一家生物制药公司，成立于 2008 年，源于 Dana-Farber 癌症研究所和 Broad Institute 的研究。公司总部位于马萨诸塞州剑桥，Agios 专注于理解和靶向细胞代谢，以开发针对癌症和罕见遗传疾病的新疗法。公司的科学平台整合了基因组发现、代谢谱分析和精准医学的方法，以识别和推进能够纠正或利用代谢功能障碍的小分子候选药物。</p>
</div><p>Agios's lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.</p>
<div class="lb-trans"><p>Agios 的主要产品是针对特定癌症突变的 IDH（异柠檬酸脱氢酶）抑制剂。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Agios Pharmaceuticals</li>
<li>Beyond NVIDIA: Picks-and-Shovels AI Plays with Strong Momentum</li>
<li>Quantum Earnings Season Is Ramping Up—What to Watch From 2 Major Players</li>
<li>Flutter Sees Post-Earnings Boost as FanDuel Shows Signs of Recovery</li>
<li>3 Healthcare Stocks Set to Benefit From the One Big Beautiful Bill</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Agios Pharmaceuticals 更好的股票</li>
<li>超越 NVIDIA：强劲势头的 AI 相关投资</li>
<li>量子财报季正在升温——关注两大主要参与者</li>
<li>Flutter 在财报后看到提振，FanDuel 显示复苏迹象</li>
<li>3 只医疗保健股票将从这项重大法案中受益</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding AGIO?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 AGIO 感兴趣的对冲基金持有什么吗？</strong> 请访问 HoldingsChannel.com，获取 Agios Pharmaceuticals, Inc.（NASDAQ:AGIO - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUdJTw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AGIO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Agios Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Agios Pharmaceuticals 吗？</h2>
</div><p>Before you consider Agios Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Agios Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agios Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Agios Pharmaceuticals 并不在名单上。</p>
</div><p>While Agios Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Agios Pharmaceuticals 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

47,414 Shares in Agios Pharmaceuticals, Inc. $AGIO Acquired by State of New Jersey Common Pension Fund D

Market Beat

新泽西州普通养老金基金 D 收购了 Agios 制药公司 47,414 股股票